Role of radiotherapy in modern treatment of Hodgkin's Lymphoma

Advances in Hematology

Volumn 2011, Issue , 2011, Pages

  Yeoh, Kheng Wei ^a   Mikhaeel, N George ^a  

^a GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED CANCER; CANCER RADIOTHERAPY; CANCER SURVIVAL; DOSIMETRY; HODGKIN DISEASE; HUMAN; PRACTICE GUIDELINE; PRIORITY JOURNAL; RADIATION DOSE; REVIEW; RISK FACTOR; SALVAGE THERAPY; TUMOR VOLUME;

EID: 78650723246     PISSN: 16879104     EISSN: 16879112     Source Type: Journal    
DOI: 10.1155/2011/258797     Document Type: Review

References (69)

1. Kaplan H. S., The radical radiotherapy of regionally localized Hodgkin's disease Radiology 1962 78 553 561
2. Kaplan H. S., Prognostic significance of the relapse-free interval after radiotherapy in Hodgkin's disease Cancer 1968 22 6 1131 1136
3. Hoppe R. T., Coleman C. N., Cox R. S., The management of stage I-II Hodgkin's disease with irradiation alone or combined modality therapy: the Stanford experience Blood 1982 59 3 455 465
4. Mauch P., Tarbell N., Weinstein H., Silver B., Goffman T., Osteen R., Zajac A., Coleman C. N., Canellos G., Rosenthal D., Stage IA and IIA supradiaphragmatic Hodgkin's disease: prognostic factors in surgically staged patients treated with mantle and paraaortic irradiation Journal of Clinical Oncology 1988 6 10 1576 1583
5. Devita V. T. Jr., Serpick A. A., Carbone P. P., Combination chemotherapy in the treatment of advanced Hodgkin's disease Annals of Internal Medicine 1970 73 6 881 895
6. Bonadonna G., Zucali R., Monfardini S., Combination chemotherapy of Hodgkin's disease with adriamycin, bleomycin, vinblastine, and imidazole carboxamide versus MOPP Cancer 1975 36 1 252 259
7. Aleman B. M. P., Van Den Belt-Dusebout A. W., Klokman W. J., Van't Veer M. B., Bartelink H., Van Leeuwen F. E., Long-term cause-specific mortality of patients treated for Hodgkin's disease Journal of Clinical Oncology 2003 21 18 3431 3439
8. Cosset J. M., Henry-Amar M., Meerwaldt J. H., Long-term toxicity of early stages of Hodgkins disease therapy: the EORTC experience-EORTC Lymphoma Cooperative Group Annals of Oncology 1991 2 2 77 82
9. Henry-Amar M., Hayat M., Meerwaldt J. H., Burgers M., Carde P., Somers R., Noordijk E. M., Monconduit M., Thomas J., Cosset J. M., Van Der Schueren E., Regnier R., Bron D., Lutsman-Marechal J., Tanguy A., De Pauw B., Tubiana M., Causes of death after therapy for early stage Hodgkin's disease entered on EORTC protocols International Journal of Radiation Oncology Biology Physics 1990 19 5 1155 1157
10. Ng A. K., Bernardo M. P., Weller E., Backstrand K. H., Silver B., Marcus K. C., Tarbell N. J., Friedberg J., Canellos G. P., Mauch P. M., Long-term survival and competing causes of death in patients with early-stage Hodgkin's disease treated at age 50 or younger Journal of Clinical Oncology 2002 20 8 2101 2108
11. Van Leeuwen F. E., Klokman W. J., Van't Veer M. B., Hagenbeek A., Krol A. D. G., Vetter U. A. O., Schaapveld M., Van Heerde P., Burgers J. M. V., Somers R., Aleman B. M. P., Long-term risk of second malignancy in survivors of Hodgkin's disease treated during adolescence or young adulthood Journal of Clinical Oncology 2000 18 3 487 497
12. Sieber M., Engert A., Diehl V., Treatment of Hodgkin's disease: results and current concepts of the German Hodgkin's Lymphoma Study Group Annals of Oncology 2000 11 1 S81 S85
13. OBrien M. M., Donaldson S. S., Balise R. R., Second malignant neoplasms in survivors of pediatric Hodgkins lymphoma treated with low-dose radiation and chemotherapy Journal of Clinical Oncology 2010 28 7 1232 1239
14. Gilbert R., Radiotherapy in Hodgkins disease. (Malignant Granulomatosis); anatomic and clinical foundations; governing principles; results American Journal of Roentgenology 1939 41 198
15. Peters M. V., A study of survivals in Hodgkins disease treated radiologically American Journal of Roentgenology 1950 63 299
16. Haybittle J. L., Hayhoe F. G. J., Easterling M. J., Review of British National Lymphoma Investigation studies of Hodgkin's disease and development of prognostic index Lancet 1985 1 8435 967 972
17. Tubiana M., Henry-Amar M., Carde P., Burgers J. M. V., Hayat M., Van Der Schueren E., Noordijk E. M., Tanguy A., Meerwaldt J. H., Thomas J., De Pauw B., Monconduit M., Cosset J. M., Somers R., Toward comprehensive management tailored to prognostic factors of patients with clinical stages I and II in Hodgkin's disease. The EORTC Lymphoma Group controlled clinical trials: 19641987 Blood 1989 73 1 47 56
18. Diehl V., Pfreundschuh M., Loffler M., Ruhl U., Hiller E., Gerhartz H., Wilmanns W., Kirchner H., Schoppe W., Petsch S., Bartels H., Pfluger K. H., Teichmann J., Fuchs R., Kuhn G., Oertel W., Mertelsmann R., Hecht T., Schalk K. P., Chemotherapy of Hodgkin's lymphoma with alternating cycles of COPP (cyclophosphamide, vincristin, procarbazine, prednisone) and ABVD (doxorubicin, bleomycin, vinblastine and dacarbazine). Reults of the HD1 and HD3 trials of the German Hodgkin Study Group Medical Oncology and Tumor Pharmacotherapy 1989 6 2 155 162
19. Schewe K. L., Reavis J., Kun L. E., Cox J. D., Total dose, fraction size, and tumor volume in the local control of Hodgkin's disease International Journal of Radiation Oncology Biology Physics 1988 15 1 25 28
20. Hanks G. E., Kinzie J. J., White R. L., Patterns of care outcome studies. Results of the national practice in Hodgkin's disease Cancer 1983 51 4 569 573
21. Thar T. L., Million R. R., Hausner R. J., McKetty M. H. B., Hodgkin's disease, stages I and II. Relationship of recurrence to size of disease, radiation dose, and number of sites involved Cancer 1979 43 3 1101 1105
22. Eghbali H., Brice P., Creemers G.-Y., Comparison of three radiation dose levels after EBVP regimen in favourable supradiaphragmatic clinical stages (CS) I-II Hodgkins lymphoma (HL): preliminary results of the EORTC-GELA H9-F trial Blood 2005 106 814a
23. Pluetschow A., Engert A., Eich H. T., Combined modality treatment of two or four cycles of ABVD followed by involved field radiotherapy in the treatment of patients with early stage Hodgkins lymphoma: update interim analysis of the randomised HD10 study of the German Hodgkins Study Group (GHSG) Blood 2005 106 2673a
24. Bonadonna G., Bonfante V., Viviani S., Di Russo A., Villani F., Valagussa P., ABVD plus subtotal nodal versus involved-field radiotherapy in early-stage Hodgkin's disease: long-term results Journal of Clinical Oncology 2004 22 14 2835 2841
25. Engert A, Schiller P., Josting A., Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with early-stage unfavourable Hodgkins lymphoma: results of the HD8 trial of the German Hodgkins Lymphoma Study Group Journal of Clinical Oncology 2003 21 3601 3608
26. Ferm C., Eghbali H., Jacobus H., Rieux C., Bosq J., Berger F., Girinsky T., Brice P., Van'T Veer M. B., Walewski J. A., Lederlin P., Tirelli U., Carde P., Van Den Neste E., Gyan E., Monconduit M., Divin M., Raemaekers J. M. M., Salles G., Noordijk E. M., Creemers G.-J., Gabarre J., Hagenbeek A., Reman O., Blanc M., Thomas J., Vi B., Kluin-Nelemans J. C., Viseu F., Baars J. W., Poortmans P., Lugtenburg P. J., Carrie C., Jaubert J., Henry-Amar M., Chemotherapy plus involved-field radiation in early-stage Hodgkin's disease New England Journal of Medicine 2007 357 19 1916 1927
27. Noordijk E. M., Carde P., Dupouy N., Hagenbeek A., Krol A. D. G., Kluin-Nelemans J. C., Tirelli U., Monconduit M., Thomas J., Eghbali H., Aleman B. M. P., Bosq J., Vovk M., Verschueren T. A. M., Pny A.-M., Girinsky T., Raemaekers J. M. M., Henry-Amar M., Combined-modality therapy for clinical stage I or II Hodgkin's lymphoma: long-term results of the European organisation for research and treatment of cancer H7 randomized controlled trials Journal of Clinical Oncology 2006 24 19 3128 3135
28. Girinsky T., van der Maazen R., Specht L., Aleman B., Poortmans P., Lievens Y., Meijnders P., Ghalibafian M., Meerwaldt J., Noordijk E., Involved-node radiotherapy (INRT) in patients with early Hodgkin lymphoma: concepts and guidelines Radiotherapy and Oncology 2006 79 3 270 277
29. Campbell B. A., Voss N., Pickles T., Morris J., Gascoyne R. D., Savage K. J., Connors J. M., Involved-nodal radiation therapy as a component of combination therapy for limited-stage Hodgkin's lymphoma: a question of field size Journal of Clinical Oncology 2008 26 32 5170 5174
30. Yahalom J., Mauch P., The involved field is back: issues in delineating the radiation field in Hodgkin's disease Annals of Oncology 2002 13 supplement 1 79 83
31. Diez P., Hoskin P. J., Aird E. G. A., Treatment planning and delivery of involved field radiotherapy in advanced Hodgkin's disease: results from a questionnaire-based audit for the UK Stanford V regimen vs ABVD clinical trial quality assurance programme (ISRCTN 64141244) British Journal of Radiology 2007 80 958 816 821
32. Cella L., Liuzzi R., Magliulo M., Radiotherapy of large target volumes in Hodgkins Lymphoma: a normal tissue sparing capability of forwards IMRT versus conventional techniques Radiation Oncology 2010 5 33
33. Lister T. A., Crowther D., Sutcliffe S. B., Glatstein E., Canellos G. P., Young R. C., Rosenberg S. A., Coltman C. A., Tubiana M., Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: cotswolds meeting Journal of Clinical Oncology 1989 7 11 1630 1636
34. Engert A., Franklin J., Eich H. T., Brillant C., Sehlen S., Cartoni C., Herrmann R., Pfreundschuh M., Sieber M., Tesch H., Franke A., Koch P., De Wit M., Paulus U., Hasenclever D., Loeffler M., Mller R.-P., Mller-Hermelink H. K., Dhmke E., Diehl V., Two cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine plus extended-field radiotherapy is superior to radiotherapy alone in early favorable Hodgkin's lymphoma: final results of the GHSG HD7 trial Journal of Clinical Oncology 2007 25 23 3495 3502
35. Nachman J. B., Sposto R., Herzog P., Gilchrist G. S., Wolden S. L., Thomson J., Kadin M. E., Pattengale P., Davis P. C., Hutchinson R. J., White K., Randomized comparison of low-dose involved-field radiotherapy and no radiotherapy for children with Hodgkin's disease who achieve a complete response to chemotherapy Journal of Clinical Oncology 2002 20 18 3765 3771
36. Meyer R. M., Gospodarowicz M. K., Connors J. M., Pearcey R. G., Bezjak A., Wells W. A., Burns B. F., Winter J. N., Horning S. J., Dar A. R., Djurfeldt M. S., Ding K., Shepherd L. E., Randomized comparison of ABVD chemotherapy with a strategy that includes radiation therapy in patients with limited-stage Hodgkin's lymphoma: national Cancer Institute of Canada Clinical Trials Group and the Eastern Cooperative Oncology Group Journal of Clinical Oncology 2005 23 21 4634 4642
37. Straus D. J., Portlock C. S., Qin J., Myers J., Zelenetz A. D., Moskowitz C., Noy A., Goy A., Yahalom J., Results of a prospective randomized clinical trial of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) followed by radiation therapy (RT) versus ABVD alone for stages I, II, and IIIA nonbulky Hodgkin disease Blood 2004 104 12 3483 3489
38. Laskar S., Gupta T., Vimal S., Consolidation radiation after remission in Hodgkins disease following six cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine chemotherapy: is there a need? Journal of Clinical Oncology 2004 22 1 62 68
39. Canellos G. P., Anderson J. R., Propert K. J., Nissen N., Cooper M. R., Henderson E. S., Green M. R., Gottlieb A., Peterson B. A., Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD New England Journal of Medicine 1992 327 21 1478 1484
40. Viviani S., Bonadonna G., Santoro A., Bonfante V., Zanini M., Devizzi L., Soncini F., Valagussa P., Alternating versus hybrid MOPP and ABVD combinations in advanced Hodgkin's disease: ten-year results Journal of Clinical Oncology 1996 14 5 1421 1430
41. Connors J. M., Klimo P., Adams G., Burns B. F., Cooper I., Meyer R. M., O'Reilly S. E., Pater J., Quirt I., Sadura A., Shustik C., Skillings J., Sutcliffe S., Verma S., Yoshida S., Zee B., Treatment of advanced Hodgkin's disease with chemotherapycomparison of MOPP/ABV hybrid regimen with alternating courses of MOPP and ABVD: a report from the National Cancer Institute of Canada Clinical Trials Group Journal of Clinical Oncology 1997 15 4 1638 1645
42. Duggan D. B., Petroni G., Johnson J., MOPP/ABV versus ABVB for advanced Hodgkins disease-preliminary report of CALGB 8952 Proceedings of the American Society of Clinical Oncology 1997 16 12. abstract 43
43. Engert A., Dreyling M., Hodgkins lymphoma: ESMO clinical recommendations for Diagnosis, treatment and follow-up Annals of Oncology 2008 19 supplement 2 65 66
44. Brusamolino E., Bacigalupo A., Barosi G., Biti G., Gobbi P. G., Levis A., Marchetti M., Santoro A., Zinzani P. L., Tura S., Classical Hodgkin's lymphoma in adults: guidelines of the Italian Society of hematology, the Italian Society of Experimental hematology, and the Italian Group for Bone Marrow Transplantation on initial work-up, management, and follow-up Haematologica 2009 94 4 550 565
45. Hutchings M., Mikhaeel N. G., Fields P. A., Nunan T., Timothy A. R., Prognostic value of interim FDG-PET after two or three cycles of chemotherapy in Hodgkin lymphoma Annals of Oncology 2005 16 7 1160 1168
46. Tsukamoto N., Kojima M., Hasegawa M., Oriuchi N., Matsushima T., Yokohama A., Saitoh T., Handa H., Endo K., Murakami H., The usefulness of 18F-fluorodeoxyglucose positron emission tomography (18F-FDG-PET) and a comparison of 18F-FDG-PET with 67 gallium scintigraphy in the evaluation of lymphoma: relation to histologic subtypes based on the World Health Organization classification Cancer 2007 110 3 652 659
47. Girinsky T., Ghalibafian M., Bonniaud G., Bayla A., Magne N., Ferreira I., Lumbroso J., Is FDG-PET scan in patients with early stage Hodgkin lymphoma of any value in the implementation of the involved-node radiotherapy concept and dose painting? Radiotherapy and Oncology 2007 85 2 178 186
48. Canellos G. P., Chemotherapy alone for early Hodgkin's lymphoma: an emerging option Journal of Clinical Oncology 2005 23 21 4574 4576
49. Meyer R. M., Is there convincing evidence for the use of chemotherapy alone in patients with limited stage Hodgkin's lymphoma? European Journal of Haematology 2005 75 66, supplement 115 120
50. Canellos G. P., Abramson J. S., Fisher D. C., LaCasce A. S., Treatment of favorable, limited-stage Hodgkin's lymphoma with chemotherapy without consolidation by radiation therapy Journal of Clinical Oncology 2010 28 9 1611 1615
51. NCCN Practice Guidelines in Oncology: Hodgkins Disease/ Lymphoma. vol. 2, 2008
52. Herbst C., Rehan F. A., Brillant C., Bohlius J., Skoetz N., Schulz H., Monsef I., Specht L., Engert A., Combined modality treatment improves tumor control and overall survival in patients with early stage Hodgkin's lymphoma: a systematic review Haematologica 2010 95 3 494 500
53. Nogov L., Reineke T., Brillant C., Sieniawski M., Rdiger T., Josting A., Bredenfeld H., Skripnitchenko R., Mller R.-P., Mller-Hermelink H.-K., Diehl V., Engert A., Lymphocyte-predominant and classical Hodgkin's lymphoma: a comprehensive analysis from the german Hodgkin study group Journal of Clinical Oncology 2008 26 3 434 439
54. Nogov L., Reineke T., Eich H. T., Josting A., Mller-Hermelink H. K., Wingbermhle K., Brillant C., Gossmann A., Oertel J., Bollen M. V., Mller R.-P., Diehl V., Engert A., Extended field radiotherapy, combined modality treatment or involved field radiotherapy for patients with stage IA lymphocyte-predominant Hodgkin's lymphoma: a retrospective analysis from the German Hodgkin Study Group (GHSG) Annals of Oncology 2005 16 10 1683 1687 (Pubitemid 41510144)
55. Longo D. L., Young R. C., Wesley M., Twenty years of MOPP therapy for Hodgkin's disease Journal of Clinical Oncology 1986 4 9 1295 1306
56. Duggan D. B., Petroni G. R., Johnson J. L., Glick J. H., Fisher R. I., Connors J. M., Canellos G. P., Peterson B. A., Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin's disease: report of an Intergroup trial Journal of Clinical Oncology 2003 21 4 607 614
57. Santoro A., Bonadonna G., Valagussa P., Long-term results of combined chemotherapy-radiotherapy approach in Hodgkin's disease: superiority of ABVD plus radiotherapy versus MOPP plus radiotherapy Journal of Clinical Oncology 1987 5 1 27 37
58. Johnson P. W. M., Radford J. A., Cullen M. H., Sydes M. R., Walewski J., Jack A. S., MacLennan K. A., Stenning S. P., Clawson S., Smith P., Ryder D., Hancock B. W., Comparison of ABVD and alternating or hybrid multidrug regimens for the treatment of advanced Hodgkin's lymphoma: results of the United Kingdom Lymphoma Group LY09 Trial Journal of Clinical Oncology 2005 23 36 9208 9218
59. Diehl V., Franklin J., Pfreundschuh M., Lathan B., Paulus U., Hasenclever D., Tesch H., Herrmann R., Drken B., Mller-Hermelink H.-K., Dhmke E., Loeffler M., Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease New England Journal of Medicine 2003 348 24 2386 2395
60. Horning S. J., Hoppe R. T., Breslin S., Bartlett N. L., William Brown B., Rosenberg S. A., Stanford V and radiotherapy for locally extensive and advanced Hodgkin's disease: mature results of a prospective clinical trial Journal of Clinical Oncology 2002 20 3 630 637
61. Gobbi P. G., Levis A., Chisesi T., Broglia C., Vitolo U., Stelitano C., Pavone V., Cavanna L., Santini G., Merli F., Liberati M., Baldini L., Deliliers G. L., Angelucci E., Bordonaro R., Federico M., ABVD versus modified Stanford V versus MOPPEBVCAD with optional and limited radiotherapy in intermediate- and advanced-stage Hodgkin's lymphoma: final results of a multicenter randomized trial by the Intergruppo Italiano Linfomi Journal of Clinical Oncology 2005 23 36 9198 9207
62. Loeffler M., Brosteanu O., Hasenclever D., Sextro M., Assouline D., Bartolucci A. A., Cassileth P. A., Crowther D., Diehl V., Fisher R. I., Hoppe R. T., Jacobs P., Pater J. L., Pavlovsky S., Thompson E., Wiernik P., Meta-analysis of chemotherapy versus combined modality treatment trials in Hodgkin's disease Journal of Clinical Oncology 1998 16 3 818 829
63. Ferm C., Sebban C., Hennequin C., Divine M., Lederlin P., Gabarre J., Ferrant A., Caillot D., Bordessoule D., Brice P., Moullet I., Berger F., Lepage E., Comparison of chemotherapy to radiotherapy as consolidation of complete or good partial response after six cycles of chemotherapy for patients with advanced Hodgkin's disease: results of the Groupe d'etudes des Lymphomes de l'Adulte H89 trial Blood 2000 95 7 2246 2252
64. Aleman B. M. P., Raemaekers J. M. M., Tirelli U., Bortolus R., Van't Veer M. B., Lybeert M. L. M., Keuning J. J., Carde P., Girinsky T., Van der Maazen R. W. M., Tomi R., Vovk M., Van Hoof A., Demeestere G., Lugtenburg P. J., Thomas J., Schroyens W., De Boeck K., Baars J. W., Kluin-Nelemans J. C., Carrie C., Aoudjhane M., Bron D., Eghbali H., Smit W. G. J. M., Meerwaldt J. H., Hagenbeek A., Pinna A., Henry-Amar M., Involved-field radiotherapy for advanced Hodgkin's lymphoma New England Journal of Medicine 2003 348 24 2396 2406 (Pubitemid 36682818)
65. Johnson P. W., Sydes M. R., Hancock B. W., Cullen M., Radford J. A., Stenning S. P., Consolidation radiotherapy in patients with advanced Hodgkin's lymphoma: survival data from the UKLG LY09 randomized controlled trial (ISRCTN97144519) Journal of Clinical Oncology 2010 28 20 3352 3359
66. Kobe C., Dietlein M., Franklin J., Markova J., Lohri A., Amthauer H., Klutmann S., Knapp W. H., Zijlstra J. M., Bockisch A., Weckesser M., Lorenz R., Schreckenberger M., Bares R., Eich H. T., Mueller R.-P., Fuchs M., Borchmann P., Schicha H., Diehl V., Engert A., Positron emission tomography has a high negative predictive value for progression or early relapse for patients with residual disease after first-line chemotherapy in advanced-stage Hodgkin lymphoma Blood 2008 112 10 3989 3994
67. Poen J. C., Hoppe R. T., Horning S. J., High-dose therapy and autologous bone marrow transplantation for relapsed/refractory Hodgkin's disease: the impact of involved field radiotherapy on patterns of failure and survival International Journal of Radiation Oncology Biology Physics 1996 36 1 3 12
68. Moskowitz C. H., Nimer S. D., Zelenetz A. D., Trippett T., Hedrick E. E., Filippa D. A., Louie D., Gonzales M., Walits J., Coady-Lyons N., Qin J., Frank R., Bertino J. R., Goy A., Noy A., O'Brien J. P., Straus D., Portlock C. S., Yahalom J., A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model Blood 2001 97 3 616 623
69. Yahalom J., Gulati S. C., Toia M., Maslak P., McCarron E. G., O'Brien J. P., Portlock C. S., Straus D. J., Phillips J., Fuks Z., Accelerated hyperfractionated total-lymphoid irradiation, high-dose chemotherapy, and autologous bone marrow transplantation for refractory and relapsing patients with Hodgkin's disease Journal of Clinical Oncology 1993 11 6 1062 1070